Author: digi

Designing Phase 3 Trials for Combination Therapies: Strategic Approaches and Regulatory Insights

June 18, 2025

Designing Phase 3 Trials for Combination Therapies: Strategic Approaches and Regulatory Insights How to Strategically Design Phase 3 Clinical Trials for Combination Therapies Why Combination Therapy Trials Require Unique Design Considerations Combination therapies—where two or more agents are administered together—are increasingly common in the treatment of complex diseases such as cancer, HIV, tuberculosis, autoimmune disorders,…

Phase 3 (Confirmation and Monitoring)

Role of Phase 4 in Device and Combination Product Monitoring

June 18, 2025

digi

Role of Phase 4 in Device and Combination Product Monitoring Phase 4 Clinical Trials for Medical Devices and Combination Products: Safety, Performance, and Regulatory Strategy Introduction With increasing innovation in drug-device integration, combination products—those that include a drug and a device, or biologic and device—have become central to modern therapeutics. Products like insulin pens, pre-filled…

Phase 4 (Post-Marketing Surveillance)

Overcoming Enrollment Barriers in Rare Disease Clinical Trials

June 18, 2025

digi

How to Overcome Enrollment Barriers in Rare Disease Clinical Trials Rare disease clinical trials face unique enrollment challenges due to limited patient populations, geographical dispersion, and lack of disease awareness. Yet, timely enrollment is critical for trial success, especially when dealing with life-threatening or progressive conditions. This tutorial offers practical strategies to overcome common recruitment…

Clinical Research Operations, Patient Enrollment Strategies

How Specialty CROs Offer Agile Trial Execution

June 17, 2025

digi

How Specialty CROs Offer Agile Trial Execution Agile Trial Execution with Specialty CROs: A Strategic Advantage In today’s fast-paced clinical research environment, the ability to execute trials with speed, flexibility, and precision is critical—especially for biotech firms, early-phase developers, and niche therapeutics. Specialty Contract Research Organizations (CROs), also known as niche CROs, are uniquely positioned…

Contract Research Organizations (CROs), Niche/Specialty CROs

Training Site Staff for Accurate SDV: Ensuring Data Integrity in Clinical Trials

June 17, 2025

digi

How to Train Site Staff for Accurate SDV in Clinical Trials Source Data Verification (SDV) is one of the most crucial aspects of clinical trial monitoring. It ensures that data reported in the Case Report Forms (CRFs) is consistent with the original source records. While CRAs are responsible for executing SDV, site staff play a…

Site Management and Monitoring, Source Data Verification

Role of Phase 1 Units and Healthy Volunteer Databases in Recruitment Efficiency

June 17, 2025

digi

Role of Phase 1 Units and Healthy Volunteer Databases in Recruitment Efficiency Enhancing Phase 1 Trial Execution Through Specialized Units and Volunteer Registries Introduction Recruitment speed and subject retention are critical success factors in Phase 1 clinical trials. Dedicated Phase 1 Units and established healthy volunteer databases play a central role in improving operational efficiency….

Phase 1 (Safety and Dosage)

Statistical Considerations for Single-Arm Studies – Clinical Trial Design and Protocol Development

June 17, 2025

digi

Statistical Considerations for Single-Arm Studies – Clinical Trial Design and Protocol Development “Analyzing Statistical Elements in Single-Arm Research Studies” Introduction to Single-Arm Studies Single-Arm studies are a type of clinical study where all participants receive the same investigational treatment. It is often used when it is considered unethical to withhold treatment from a control group,…

Clinical Trial Design and Protocol Development, Single-Arm Trials

SDV and SDR During Routine Monitoring Visits: A Comprehensive Guide

June 17, 2025

digi

Mastering SDV and SDR During Routine Monitoring Visits Routine Monitoring Visits (RMVs) are essential for maintaining the quality and compliance of clinical trials. Two core activities performed during these visits are Source Data Verification (SDV) and Source Data Review (SDR). While often used interchangeably, these terms have distinct meanings and roles in ensuring data integrity….

Routine Monitoring Visits, Site Management and Monitoring

SMS and Email Reminders to Improve Visit Compliance in Clinical Trials

June 17, 2025

digi

SMS and Email Reminders to Improve Visit Compliance in Clinical Trials Boosting Visit Compliance in Clinical Trials with SMS and Email Reminders In clinical trials, consistent visit attendance is vital for data integrity, protocol adherence, and participant safety. Yet, missed or delayed visits remain a significant challenge, often leading to deviations, increased trial duration, and…

Patient Engagement Tools, Patient Recruitment and Retention

Ensuring Protocol Compliance During Home Visits in Decentralized Trials

June 17, 2025

digi

Ensuring Protocol Compliance During Home Visits in Decentralized Trials Best Practices for Ensuring Protocol Compliance During Home Visits in DCTs Decentralized clinical trials (DCTs) have brought clinical research closer to patients by incorporating home health visits. While this model increases accessibility and retention, it also presents new challenges in ensuring protocol compliance outside traditional clinical…

Decentralized Clinical Trials (DCTs), Home Health Visits